Sinovac Biotech Ltd. SVA, said Wednesday that a Phase 1/2 clinical trial of its COVID-19 vaccine in children and adolescents between the ages of 3 and 17 demonstrated that the shot is safe and produced a strong antibody response, according to a study ...
from Google Alert - health https://ift.tt/3hmSZqB
via IFTTT
0 comments:
Post a Comment